Media.Player

Neurotherapeutic Drug Delivery via Focused Ultrasound

总结

Elisa E. Konofagou Ph.D..

技术优势

Minimally invasive due to transient creation of small BB openingSafe and quick relative to techniques such as cranial surgeryNon-toxic compared to drug-based methods for BBB disruptionHighly localized for access to specific regions of the brainBased on FDA approved technologies: MRI, ultrasound and microbubblesPatent information:Patent Issued (US20090005711Patent Issued (WO/2007/035721Tech Ventures Reference: IR M09-025

技术应用

Non-invasive administration of compounds that are currently only delivered via trans-cranial surgeryReviving drug candidates that were formerly dropped from developmentNeurological disorders with focal pathologies could be specifically targeted for drug delivery (e.g., Alzheimer's and Parkinson's)Treatment of psychiatric disordersAnesthetizing specific portions of the brain while leaving other portions unaffected

详细技术说明

Elisa E. Konofagou Ph.D..

*Abstract

None

*Inquiry

Satish RaoColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

M09-025

*Principal Investigation

*Publications

Choi JJ, Wang S, Tung YS, Morrison B 3rd, Konofagou EE. "Molecules of various pharmacologicallyrelevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo". Ultrasound Med Biol.2010 Jan;36(1):58-67.

*Web Links

WIPO: US Pat App 20110295105

国家/地区

美国